55.68  2.51 (4.72%)		10-29 16:00
Open: 55 High: 55.945 Volume: 2,120,726		Pre. Close: 53.17 Low: 53.16 Market Cap: 3,122(M)

Short term
Mid term
Targets	6-month :	65.34	1-year :	76.32
Resists	First :	55.94	Second :	65.34
Pivot price	50.97
Supports	First :	49.99	Second :	46.31
MAs	MA(5) :	53.28	MA(20) :	50.26
	MA(100) :	41.14	MA(250) :	37.21
MACD	MACD :	1.9	Signal :	1.5
%K %D	K(14,3) :	82.5	D(3) :	82
RSI	RSI(14): 82.4
52-week	High :	55.94	Low :	29.15

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SUPN ] has closed It is unclear right now based on current values. 65.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	56.01 - 56.22	56.22 - 56.39
Low:	52.61 - 52.87	52.87 - 53.07
Close:	55.28 - 55.69	55.69 - 56.02

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Wed, 29 Oct 2025
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus

Wed, 29 Oct 2025
Supernus a new buy at BofA on 'underappreciated' CNS assets - Seeking Alpha

Wed, 29 Oct 2025
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - Yahoo Finance

Wed, 29 Oct 2025
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus

Wed, 29 Oct 2025
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq

Wed, 29 Oct 2025
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	56 (M)
Shares Float	49 (M)
Held by Insiders	3.8 (%)
Held by Institutions	97 (%)
Shares Short	4,950 (K)
Shares Short P.Month	5,020 (K)

EPS	1.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.95
Profit Margin	9.6 %
Operating Margin	6.7 %
Return on Assets (ttm)	2.3 %
Return on Equity (ttm)	6.3 %
Qtrly Rev. Growth	-1.8 %
Gross Profit (p.s.)	10.5
Sales Per Share	11.86
EBITDA (p.s.)	2.35
Qtrly Earnings Growth	11.1 %
Operating Cash Flow	187 (M)
Levered Free Cash Flow	150 (M)

PE Ratio	48.41
PEG Ratio	0
Price to Book value	2.93
Price to Sales	4.69
Price to Cash Flow	16.68

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.